Accelerating Drug Discovery
with AI
The drug discovery cycle takes 10–15 years and costs billions. WeDaita was built to compress that timeline— giving researchers AI-native tools that eliminate bottlenecks from target identification to clinical insights.
Purpose-Built for Drug Discovery
To accelerate drug discovery by eliminating inefficiencies in biomedical research—unlocking faster, more scalable innovation through AI-native tools and integrated data workflows.
Delivers AI-driven solutions that address the core pain points of biomedical research: siloed data, manual analysis, fragmented workflows, and slow insight generation using our intelligent biomedical AI platform powered by advanced AI agents and WeDaita MCP services.
Three Pillars of BioMedAI
Every feature starts with a real scientific problem. We partner with researchers to ensure the platform reflects how biology actually works—not just how software is typically built.
Built on large language models, multi-agent orchestration, and WeDaita MCP services—so AI is the core reasoning layer, not a bolt-on feature on top of legacy software.
From target identification and database retrieval to ADME prediction and clinical trial analysis— a single connected workflow replacing dozens of fragmented tools.
Star of the Month
I have strong experiences on the development of computational protocols for structure-based inhibitor design, such as protein-ligand scoring function development (both classical and machine-learning methods). Prospective virtual screening of compound library in early-stage drug discovery.
I am an AI scientist and entrepreneur with over a decade of experience in immuno-oncology, infectious diseases, and computational biology. With a Master’s degree in Computer Science and a PhD in Infectious Diseases, my work sits at the intersection of machine learning, software engineering, and drug discovery. I am the founder of Wedaita, where I am building BioMedAI, an AI-driven platform designed to accelerate drug discovery and shorten the time required to bring life-saving therapies to patients using generative AI and autonomous multi-agent workflows. My focus is on developing end-to-end AI systems that integrate biological data, predictive modeling, and scalable software infrastructure to enable faster and more efficient therapeutic development. My goal is to leverage AI to fundamentally transform how drugs are discovered, designed, and optimized.
Ready to See BioMedAI in Action?
Explore the full platform or book a live demo with our team and see how WeDaita compresses the drug discovery timeline for your organisation.